

# **NYMOX appoint experienced CFO Danielsen**

**Nymox Pharmaceutical Corp. {NASDAQ: NYMX}** have announced the appointment of a new CFO to take over from the departing incumbent, Andre Monett.

Erik Danielsen has worked with NYMOX over the years and has a “deep understanding of the dynamics”

HASBROUCK HEIGHTS, N.J., July 13, 2015 – **Nymox Pharmaceutical Corp. {NASDAQ: NYMX}** is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company. Mr. Danielsen is a highly experienced financial analyst with special expertise in emerging health care companies, and with extensive international business knowledge.

Mr. Danielsen received his MBA from the University of Freiburg in 1987. He was formerly Senior Auditor for Price Waterhouse, and subsequently was Equity Strategist for Credit Suisse, and Equity Analyst for Credit Suisse First Boston. Mr Danielsen was formerly CEO of Analitika, an equity research, consulting and fund raising firm based in Switzerland.

**Dr. Paul Averbach CEO** said, *“Erik has worked with Nymox and Nymox shareholders for many years and has an excellent working understanding of the dynamics of our Company. He will be a superb addition for the Company both on an operational level and at many strategic levels. We are delighted to welcome Erik to the team.”*

*“On behalf of Management and the Board, I wish to thank our departing CFO Andre Monette for his very solid performance helping the Company during the past year. We wish Andre the*

*very best moving forward."*

For more information please contact [info@nymox.com](mailto:info@nymox.com)

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Factors that could cause actual results or events to differ materially from those projected in forward-looking statements are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

**CONTACT:**

[Paul Averback](#)

[Nymox Pharmaceutical Corporation](#)

[+1 514 332 3222](#)

[www.nymox.com](http://www.nymox.com)